Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/217574TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION
WO 04.11.2021
Int.Class C07D 215/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
38Nitrogen atoms
42attached in position 4
46with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Appl.No PCT/CN2020/088241 Applicant WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. Inventor CUI, Jian
A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof to the subject in need thereof, wherein R1 is OH or H, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus.
2.WO/2021/195763ANTIVIRAL RUTHENATE(III) THERAPEUTICS
WO 07.10.2021
Int.Class A61K 31/416
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
Appl.No PCT/CA2021/050423 Applicant BOLD THERAPEUTICS INC. Inventor MCALLISTER, Edward Russell
Methods are provided for treating a viral disease, involving use of an effective amount of sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] in a subject at risk of or suffering from a viral infection, such as a lung infection. The virus may be a coronavirus or a β coronavarius of group 2B, for example a SARS-CoV-2.
3.2021105627In silico evaluation and synthesis of novel sulfonamides as promising anti-viral drugs docked against anti-COVID-19 protein targets: SARS-CoV-2 main protease
AU 28.10.2021
Int.Class C07D 295/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
22with hetero atoms directly attached to ring nitrogen atoms
26Sulfur atoms
Appl.No 2021105627 Applicant Bobbala, Prathima DR Inventor
COVID-19 pandemic has led us to design and develop novel organic molecules as medicinally promising drugs which can prevent the SARS-CoV-2 virus of the infected patients. The current invention provides potential anti-viral drugs docked against anti COVID-19 protein targets: SARS-CoV-2 main protease, drug-likeness, efficacy, molecular docking, physicochemical and pharmacokinetic studies of novel synthesized sulfonamide analogues. Physicochemical and pharmacokinetic properties have been evaluated on the basis of certain parameters like Lipinski rule of 5 (RO5 rule) and ADMET (absorption, distribution, metabolism, excretion and toxicity). All the synthesized compounds follow Lipinski rule of five (RO5 rule) and the compounds followed the range of rotational bonds, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), topological surface area (TPSA), number of violations, etc. All these compounds shown good pharmacokinetic properties, zero renal OCT2 substrate toxicity and negligible toxicity values. BOILED-egg model was carried out for evaluating the gastrointestinal absorption and brain penetration effect. Compounds 3b and 3d comes under white region of egg and exhibited good gastrointestinal absorption, whereas, 3a, 3c, 3e and 3f compounds fall under yellow region (yolk) of egg which showed good brain penetration effect. All novel sulfonamide analogues including commercially available anti-COVID-19 drugs, Hydroxychloquine and Umifenovir docked with anti-COVID-19 protein targets, i.e., PDB: 6VWW & 6Y2E. Compound 3c when docked with PDB: 6VWW shown maximum energy of -22.06 kcal/mol with two hydrogen binding interactions which are better than marketed drugs. Similarly, compound 3a exhibited highest energy of-14.00kca/mol.
4.WO/2021/206799COMPOUNDS FOR THE TREATMENT OF SARS
WO 14.10.2021
Int.Class A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
Appl.No PCT/US2021/017271 Applicant PURDUE RESEARCH FOUNDATION Inventor MITSUYA, Hiroaki
Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.
5.WO/2021/225767METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2
WO 11.11.2021
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/US2021/027535 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor BAKOWSKI, Malina A.
Disclosed herein are methods that are useful for treating a subject who has a pathogenic infection, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); reducing the likelihood of the subject from being infected by a pathogen; and for reducing the transmission of a pathogen from a subject to others. The methods utilize a compound disclosed in Table 1 or Table 4 herein, optionally in combination with an additional agent such as an anti-infective agent.
6.2021106444COMPUTER-AIDED DRUG DESIGN AND GREEN SYNTHESIS OF NOVEL PYRAZOLE ANALOGUES AS POTENTIAL SARS-COV-2 MAIN PROTEASE INHIBITORS AGAINST ANTI-COVID-19 PROTEIN TARGETS
AU 11.11.2021
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 2021106444 Applicant Bobbala, Prathima DR Inventor
COVID-19 pandemic has significantly increased high deaths, infectivity and hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a foremost problem in the world presently. Currently, all research institutions and pharmaceutical industries are keen in developing new vaccines and more effective drugs that could inhibit the SARS-CoV-2 virus and help in the treatment of patients. This provoked us to design medicinally effective drug candiadates which can prevent the SARS-CoV-2 virus of the infected patients. The present invention offers most promising anti-viral drugs docked against anti-COVID-19 protein targets: SARS-CoV-2 main protease, efficacy, drug-likeness, molecular docking, BOILED-EGG model, physicochemical and pharmacokinetic studies of novel synthesized polysubstituted 4,7-dihydro 1H-pyrazolo[3,4-b]pyridin-6-amine analogues. All the novel synthesized analogues including commercially available anti-COVID-19 drugs, Hydroxychloroquine and Umifenovir docked with anti-COVID-19 protein targets, i.e., PDB: 6LU7 and 6Y2E. This current invention further provides a rapid access to novel 4,7-dihydro-H-pyrazolo[3,4-b]pyridin-6-amines and few advantages are milder reaction conditions, short reaction times, easy work-up, excellent yields, effective SARS-CoV-2 main protease inhibitors and use of ultrasonic radiation via green synthesis.
7.WO/2021/195406NEW THERAPEUTIC USES OF COMPOUNDS
WO 30.09.2021
Int.Class A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
Appl.No PCT/US2021/024193 Applicant PROXIMAGEN, LLC Inventor PULLMAN, William
The present invention relates to the treatment and prevention of pulmonary inflammation using a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, and/or prodrug thereof. The pulmonary inflammation may be associated with acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), which in turn may be associated with viral induced cytokine surge. Such diseases and conditions may be caused by a coronavirus, i.e., severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
8.WO/2021/212054METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS
WO 21.10.2021
Int.Class A61K 31/426
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
Appl.No PCT/US2021/027803 Applicant CIRIUS THERAPEUTICS, INC. Inventor COLCA, Gerard, R.
Provided herein are thiazolidinedione analogues that are useful for treating metabolic disorders and/or coronavirus infections. In some embodiments, the metabolic disorder includes insulin resistance, diabetes, or prediabetes. In some embodiments, the coronavirus is COVID-19.
9.WO/2021/184128METHODS OF TREATING A CORONAVIRUS INFECTION USING COLCHICINE
WO 23.09.2021
Int.Class A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
Appl.No PCT/CA2021/050368 Applicant INSTITUT DE CARDIOLOGIE DE MONTREAL Inventor TARDIF, Jean-Claude
Disclosed are methods of treating a coronavirus infection (e.g., a SARS-CoV-2 infection) using colchicine, and methods of treating Kawasaki Disease or Kawasaki Disease Shock Syndrome, e.g., by administering colchicine to a subject in need thereof.
10.20090137818Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
US 28.05.2009
Int.Class A61K 31/422
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
422not condensed and containing further heterocyclic rings
Appl.No 11273270 Applicant Universitat zu Luebeck Inventor Hilgenfeld Rolf

The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.